
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q I saw a 3-year-old boy for his well-child checkup recently. His mother mentioned that he has always been sensitive to smells, but over the past six months the problem has reached dramatic proportions.






